sitimagene ceradenovec

AXP000147.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, E1-deleted, HSV-TK)
Originator
Ark Therapeutics
Sponsor
Ark Therapeutics

Names

NameTypeSource
sitimagene ceradenovecpreferred name, INNcurator, ncit
Cereprobrandpress
EG-009 ambiguouscodencit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
E1-deleted adenoviral vector encoding HSV thymidine kinase; given with intravenous ganciclovir
Transgenes
HSV-TK
Route
intracerebral
Source
evidence

Cross-references

NCI Thesaurus
C162553

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 34710575Are Two-Dimensional Morphometric Measures Reflective of Disease Severity in Adult Chiari I Malformation?World neurosurgery2022name in abstract: Cerepro
PMID 23850491Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.The Lancet. Oncology2013name in title: sitimagene ceradenovec
PMID 22677751[The use of cerepro (choline alfoscerate) in the treatment of outpatients with chronic progressive cerebrovascular disease].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2012name in title: Cerepro

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 36511461[Physical factors in the medical rehabilitation of patients with chronic cerebral ischemia in the outpatient stage].Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury2022name in abstract: Cerepro
PMID 28560211Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.Frontiers in medicine2017name in abstract: Cerepro
PMID 26052534Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.Molecular therapy. Methods & clinical development2015name in abstract: Cerepro
PMID 24352098Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme.Cancer biology & therapy2014name in title: sitimagene ceradenovec
PMID 21142657Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.Future oncology (London, England)2010name in title: sitimagene ceradenovec
PMID 19367582A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration.The journal of gene medicine2009name in title: Cerepro
PMID 18386231Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma.Current opinion in molecular therapeutics2008name in title: sitimagene ceradenovec
PMID 20021420Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications.Current molecular pharmacology2008name in abstract: Cerepro
PMID 18477977[The experience of the use of cerepro in the treatment of out-patients in the early period of rehabilitation of is ischemic stroke.].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2007name in title: Cerepro

Notes

Cerepro: adenoviral HSV thymidine kinase injected into the wall of the resection cavity after surgery for high-grade glioma, followed by intravenous ganciclovir. The CHMP adopted a negative opinion and Ark withdrew the EU application on 8 March 2010 during re-examination; never approved. EG-009 is the development code.

How to cite

sitimagene ceradenovec (AXP000147.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000147.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.